ROCK1,2 bind ROCKi

Stable Identifier
R-HSA-9680443
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Ripasudil (Glanatec), as its hydrochloride hydrate (K-115), is a specifc Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor (ROCKi) used for the treatment of glaucoma and ocular hypertension in Japan (Garnock-Jones 2014). Netarsudil is a USA-approved ROCKi used to treat glaucoma and ocular hypertenstion (Sturdivant et al. 2016, Tanna & Johnson 2018).

Literature References
PubMed ID Title Journal Year
30007591 Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension

Tanna, AP, Johnson, M

Ophthalmology 2018
27072905 Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma

Sturdivant, JM, Royalty, SM, Lin, CW, Moore, LA, Yingling, JD, Laethem, CL, Sherman, B, Heintzelman, GR, Kopczynski, CC, deLong, MA

Bioorg. Med. Chem. Lett. 2016
25414122 Ripasudil: first global approval

Garnock-Jones, KP

Drugs 2014
Participants
Participant Of
Authored
Reviewed
Created
Cite Us!